The Sec61 translocon is a therapeutic vulnerability in multiple myeloma

The Sec61 translocon is a therapeutic vulnerability in multiple myeloma

Abstract Multiple myeloma (MM) is an incurable malignancy characterized by the uncontrolled expansion of plasma cells in the bone marrow. While proteasome inhibitors like bortezomib efficiently halt MM progression, drug resistance inevitably develop, and novel therapeutic approaches are needed. Here...

Full description

Bibliographic Details
Main Authors: Antoine Domenger, Caroline Choisy, Ludivine Baron, Véronique Mayau, Emeline Perthame, Ludovic Deriano, Bertrand Arnulf, Jean‐Christophe Bories, Gilles Dadaglio, Caroline Demangel
Format: Article
Language:English
Published: Springer Nature 2022-03-01
Series:EMBO Molecular Medicine
Subjects:
multiple myeloma
proteostatic stress
Sec61 translocon
Online Access:https://doi.org/10.15252/emmm.202114740

Internet

https://doi.org/10.15252/emmm.202114740

Similar Items